US biotech firm Incyte (Nasdaq: INCY) and Cellenkos, a Houston USA-based associate of Hong Kong-based firm Golden Meditech (SEHK: 00801), have signed a development collaboration to investigate the combination of ruxolitinib (Jakafi) and CK0804, Cellenkos’ cryopreserved CXCR4 enriched, allogeneic, umbilical cord blood-derived T-regulatory cells, in patients with myelofibrosis (MF).
In addition, Incyte has an exclusive option to acquire sole rights to develop and commercialize CK0804, and genetically-modified variants of CK0804, in benign and malignant hematology indications.
Shares of Incyte traded up as much as 4% on Wednesday, when it closed the day 1.15% higher at $86.86. Jakafi, approved for the treatment of hematologic, oncologic and other indications, is expected to bring in net product revenue in a range of $1.91 billion to $1.94 billion for full-year 2020, according to the latest guidance from the company,
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze